
AI Digest · FDA reportedly ends fast review program as Compass Pathways files psilocybin application
Kalshi traders heavily favor no FDA approval of any psychedelic drug this year, though approval gained ground over the last day. The FDA is reportedly ending a program that cut drug reviews to one or two months. Drug developer Compass Pathways filed its psilocybin application and still expects a first-half 2027 launch. Drug developer Helus Pharma said on Monday its psychedelic depression drug beat placebo in a Phase 3 trial. Serious adverse events in the study raised safety questions.